{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:18:30Z","timestamp":1787505510858,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semradonc.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:28:07Z","timestamp":1757514487000},"page":"489-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State"],"prefix":"10.1016","volume":"35","author":[{"given":"John","family":"Starner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ruh","family":"Wuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyn A.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4789-449X","authenticated-orcid":false,"given":"Leila T.","family":"Tchelebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semradonc.2025.07.009_bib0001","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semradonc.2025.07.009_bib0002","unstructured":"Cancer Stat Facts: Pancreatic Cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html#:\u223c:text=Estimated%20New%20Cases%20in%202024,12.8%25%202014%E2%80%932020. Accessed March 18, 2025."},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semradonc.2025.07.009_bib0004","unstructured":"Annual Cancer Facts & Figures. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures.html. Accessed March 18, 2025."},{"key":"10.1016\/j.semradonc.2025.07.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.009_bib0006","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.009_bib0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.14701\/ahbps.23-149","article-title":"Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma","volume":"28","author":"Ang","year":"2024","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.009_bib0008","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s11605-020-04870-6","article-title":"Impact of resection margin status in patients with pancreatic cancer: A national cohort study","volume":"25","author":"Kaltenmeier","year":"2021","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.009_bib0009","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejso.2008.12.006","article-title":"Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma","volume":"35","author":"Van den broeck","year":"2009","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.009_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gassur.2005.09.016","article-title":"Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings","volume":"10","author":"Hishinuma","year":"2006","journal-title":"J Gastrointest Surg."},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.009_bib0011","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/MPA.0000000000002162","article-title":"Challenges in recruitment and retention: leveraging health-related antecedents and information carrier factors to improve patient participation in pancreatic cancer research-a review article","volume":"51","author":"Coffin","year":"2022","journal-title":"Pancreas"},{"issue":"20","key":"10.1016\/j.semradonc.2025.07.009_bib0012","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.21.02492","article-title":"Eligibility criteria perpetuate disparities in enrollment and participation of black patients in pancreatic cancer clinical trials","volume":"40","author":"Riner","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.009_bib0013","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1200\/EDBK_159117","article-title":"The past, present, and future of pancreatic cancer clinical trials","volume":"5","author":"Matrisian","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.009_bib0014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.009_bib0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.semradonc.2025.07.009_bib0016","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.009_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with Gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.semradonc.2025.07.009_bib0018","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.009_bib0019","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.009_bib0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","article-title":"Fluorouracil vs Gemcitabine chemotherapy before and after Fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial","volume":"299","author":"Regine","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.009_bib0021","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.009_bib0022","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.ijrobp.2012.04.035","article-title":"Five year results of US intergroup\/RTOG 9704 with postoperative CA 19-9 \u226490 U\/mL and comparison to the CONKO-001 trial","volume":"84","author":"Berger","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.009_bib0023","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704\u2014A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"10.1016\/j.semradonc.2025.07.009_bib0024","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10073","key":"10.1016\/j.semradonc.2025.07.009_bib0025","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.semradonc.2025.07.009_bib0026","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.009_bib0027","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.009_bib0028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COC.0000000000000633","article-title":"Results of the NRG oncology\/RTOG 0848 adjuvant chemotherapy question-Erlotinib+Gemcitabine for resected cancer of the pancreatic head: A phase II randomized clinical trial","volume":"43","author":"Abrams","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1016\/j.semradonc.2025.07.009_bib0029","article-title":"NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy \u00b1 chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)","volume":"42","author":"Abrams","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.009_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijrobp.2023.08.014","article-title":"Analysis of radiation Therapy quality assurance in NRG oncology RTOG 0848","volume":"118","author":"Tchelebi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.009_bib0031","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.hpb.2023.06.018","article-title":"National adoption of neoadjuvant chemotherapy: Paradigm shift in the treatment of pancreatic cancer","volume":"25","author":"Nassour","year":"2023","journal-title":"HPB (Oxford)"},{"issue":"11","key":"10.1016\/j.semradonc.2025.07.009_bib0032","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.009_bib0033","doi-asserted-by":"crossref","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial","volume":"34","author":"Koerkamp","year":"2023","journal-title":"ESMO Ann Oncol"},{"issue":"30","key":"10.1016\/j.semradonc.2025.07.009_bib0034","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.semradonc.2025.07.009_bib0035","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","article-title":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","volume":"25","author":"Groot","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.009_bib0036","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.07.009_bib0037","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.adro.2018.11.007","article-title":"Initial results of a prospective study of adjuvant pancreatic stereotactic body radiation therapy for close or positive margins","volume":"4","author":"Bernard","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.009_bib0038","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2024.10.039","volume":"121","author":"Hill","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:10:29Z","timestamp":1760227829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1053429625000633"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.009","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}